AURORA, Colo. (February 8, 2021) – Researchers from the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus have discovered that immune responses to insulin may help identify the most vulnerable. the risk for developing Type 1 diabetes.
The study, recently released in the Proceedings of the National Academy of Sciences, have measured immune responses from genetically predisposed individuals to developing Type 1 diabetes (T1D) to insulin and hybrid insulin peptides. Since not all genetically predisposed people develop T1D, researchers sought to study T-cell immune responses from the peripheral blood that may occur before the onset of clinical diabetes. .
“We want to find out why people develop T1D, and this research has helped to provide a lot more information and data on what it’s like when people are exposed. half at genetic risk goes to clinical diagnosis, “said Aaron Michels, MD, director of the researcher study, Associate Professor of Medicine at CU Anschutz and researcher at the Barbara Davis Center. with you, you want to treat disease when it is active, so this is a useful in our field to understand when people have an immune response against insulin – producing cells. “
Researchers collected blood samples from genetically endangered adolescents every 6 months for two years. T-cell inflammatory responses to hybrid insulin peptides are associated with worsening blood glucose uptake and progression to T1D development. The results show significant improvement in early identification of T1D risk as well as potential for intervention.
“Medications are now being used in research studies that have delayed the onset of clinical type 1 diabetes,” says Michels. “Patients with these specific immune responses may benefit from immune intervention to delay T1D and possibly prevent it for years.”
Moreover, Michels argues that these results may lead to research beyond T1D. “Our work focused on diabetes, but this has an impact on other autoimmune diseases. Understanding how the immune system responds can be crucial in trying to prevent put on disease before clinical symptoms appear. “
###
About the University of Colorado Anschutz Medical Campus
The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformational science, medicine, education, and patient care. The campus includes the University of Colorado health professional schools, more than 60 institutes and institutes, and two nationally registered independent hospitals that treat more than two million adult and pediatric patients each year. Innovative, interconnected and highly collaborative, we deliver life-changing therapies, patient care, professional training, and conduct research that is world-renowned. For more information, visit http: // www.
Disclaimer: AAAS and EurekAlert! they are not responsible for the accuracy of press releases posted to EurekAlert! by sending institutions or for using any information through the EurekAlert system.